[go: up one dir, main page]

ZA200902814B - Compositions and methods for diagnosing, treating, and preventing prostate conditions - Google Patents

Compositions and methods for diagnosing, treating, and preventing prostate conditions

Info

Publication number
ZA200902814B
ZA200902814B ZA200902814A ZA200902814A ZA200902814B ZA 200902814 B ZA200902814 B ZA 200902814B ZA 200902814 A ZA200902814 A ZA 200902814A ZA 200902814 A ZA200902814 A ZA 200902814A ZA 200902814 B ZA200902814 B ZA 200902814B
Authority
ZA
South Africa
Prior art keywords
diagnosing
compositions
treating
methods
preventing prostate
Prior art date
Application number
ZA200902814A
Other languages
English (en)
Inventor
Carlton D Donald
Original Assignee
Musc Found For Res Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Musc Found For Res Dev filed Critical Musc Found For Res Dev
Publication of ZA200902814B publication Critical patent/ZA200902814B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G01N33/57555—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200902814A 2007-01-16 2008-01-16 Compositions and methods for diagnosing, treating, and preventing prostate conditions ZA200902814B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88514207P 2007-01-16 2007-01-16

Publications (1)

Publication Number Publication Date
ZA200902814B true ZA200902814B (en) 2010-08-25

Family

ID=39636676

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200902814A ZA200902814B (en) 2007-01-16 2008-01-16 Compositions and methods for diagnosing, treating, and preventing prostate conditions

Country Status (15)

Country Link
US (3) US8088603B2 (es)
EP (1) EP2104744B1 (es)
JP (1) JP5653042B2 (es)
KR (1) KR101565080B1 (es)
CN (1) CN101970685B (es)
AP (1) AP2009004851A0 (es)
AU (1) AU2008206258B2 (es)
BR (1) BRPI0806779A2 (es)
CA (1) CA2667364A1 (es)
ES (1) ES2390083T3 (es)
IL (1) IL198677A (es)
MX (1) MX2009007564A (es)
NZ (2) NZ578164A (es)
WO (1) WO2008089236A2 (es)
ZA (1) ZA200902814B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2772158B2 (ja) 1991-05-30 1998-07-02 三菱重工業株式会社 橋桁の架設方法
US20120071347A1 (en) * 2005-10-14 2012-03-22 Phigenix, Inc. Compositions and methods for monitoring and detecting cancerous conditions
US20100029504A1 (en) * 2007-01-16 2010-02-04 Phigenix, Inc. Detecting pax2 for the diagnosis of breast cancer
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
US8461126B2 (en) 2005-10-14 2013-06-11 Phigenix, Inc. Targeting EN2, PAX2, and/or DEFB1 for treatment of prostate conditions
RU2016133412A (ru) * 2009-08-24 2018-12-10 Фидженикс, Инк. Целенаправленное воздействие на pax2 для лечения рака молочной железы
US9255931B2 (en) 2010-06-24 2016-02-09 Morehouse School Of Medicine Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
WO2013085483A1 (en) * 2011-12-05 2013-06-13 Phigenix, Inc. Targeting en2, pax2, and/or defb1 for treatment of prostate conditions
EP2861988B1 (en) * 2012-06-14 2019-05-22 The Whitehead Institute for Biomedical Research Genome-wide method of assessing interactions between chemical entities and their target molecules
WO2014113701A1 (en) 2013-01-20 2014-07-24 Dyax Corp. Evaluation, assays and treatment of pkal-mediated disorders
WO2015161189A1 (en) * 2014-04-17 2015-10-22 Cornell University Neat1 as a prognostic marker and therapeutic target for prostate cancer
CN113552350B (zh) * 2015-04-21 2024-10-11 基因泰克公司 用于前列腺癌分析的组合物和方法
EP3391048B1 (en) 2015-12-15 2021-07-07 Case Western Reserve University Oral squamous cell carcinoma evaluation using beta defensin
US11732258B2 (en) * 2016-11-02 2023-08-22 President And Fellows Of Harvard College Engineered guide RNA sequences for in situ detection and sequencing
CN111454916A (zh) * 2019-01-18 2020-07-28 王泽宋 甘油醛-3-磷酸脱氢酶蛋白或其免疫性片段的新应用
CN109781988A (zh) * 2019-02-28 2019-05-21 贵州省人民医院 采用her2基因扩增法检测乳腺癌循环肿瘤细胞的特异性方法
AU2020258869A1 (en) 2019-04-16 2021-11-25 Takeda Pharmaceutical Company Limited Methods for quantitation of functional C1 esterase inhibitor (fC1-INH)
CN110907650A (zh) * 2019-11-18 2020-03-24 复旦大学附属儿科医院 应用纳米磁珠富集尿液沉渣pax2蛋白作为诊断原发性膀胱输尿管反流生物标志物的用途
CN113272013A (zh) 2019-12-17 2021-08-17 奇努克医疗公司 用阿曲生坦治疗IgA肾病的方法
CN112646895A (zh) * 2021-01-22 2021-04-13 深圳科诺医学检验实验室 检测基因表达量的引物、探针、试剂盒、检测方法及应用
CN113658696B (zh) * 2021-07-22 2023-07-14 四川大学华西医院 一种基于患者年龄、营养指标、肿瘤分期和肿瘤标志物联合预测胃癌预后的预测系统
CN114045336B (zh) * 2021-09-28 2024-01-02 中国人民解放军空军军医大学 Cga基因作为靶点在制备用于诊断和治疗耐药实体瘤药物的应用
CN114113633B (zh) * 2021-12-27 2024-05-24 复旦大学 用于前列腺癌危险度诊断和疗效评估的分子指标、试剂盒
CN116987680A (zh) * 2022-04-25 2023-11-03 复旦大学 支链氨基酸转氨酶1的功能获得性突变体及其应用
CN119708130A (zh) * 2023-09-20 2025-03-28 烟台蓝纳成生物技术股份有限公司 丹磺酰胺修饰的psma靶向化合物及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
EP1084273A1 (en) 1998-06-06 2001-03-21 Genostic Pharma Limited Probes used for genetic profiling
US6699973B1 (en) 1998-11-19 2004-03-02 Elan Corporation, Plc Antibodies to peptides that target GIT receptors and related methods
GB9903841D0 (en) * 1999-02-20 1999-04-14 Imp College Innovations Ltd Diagnosis and treatment of cancer
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US20030092657A1 (en) * 1999-12-22 2003-05-15 Paul Goodyer Modulation of PAX-2 for controlled apoptosis or survival of cells
US20050079492A1 (en) * 2000-09-12 2005-04-14 Burgess Jr. Robert M. Micro-arrayed organization of transcription factor target genes
AU2001291049A1 (en) * 2000-09-15 2002-03-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer Defensin-antigen fusion proteins
EP1373896A2 (en) * 2001-03-12 2004-01-02 MonoGen, Inc. Cell-based detection and differentiation of disease states
AU2003287366A1 (en) * 2002-10-31 2004-06-07 University Of Rochester Hyfroxyflutamide induced pathways related to androgen receptor negative prostate cancer cells
US20060135422A1 (en) * 2003-04-17 2006-06-22 Moskowitz David W Use of angiotensin receptor blockers (ARBs) to treat diseases associated with excess ACE
US8673634B2 (en) 2003-11-13 2014-03-18 Massachusetts Eye & Ear Infirmary Method for the treatment of hearing loss
CA2599393A1 (en) * 2005-02-25 2006-08-31 The Regents Of The University Of Michigan Small molecule inhibitors of stat3 and the uses thereof
US20070166728A1 (en) 2005-07-22 2007-07-19 Alphagenics, Inc. Genetic profile imaging and data-sharing device and methodology for socially relevant traits
EP2189522A1 (en) * 2005-10-14 2010-05-26 MUSC Foundation For Research Development Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy

Also Published As

Publication number Publication date
WO2008089236A2 (en) 2008-07-24
MX2009007564A (es) 2009-12-08
BRPI0806779A2 (pt) 2011-09-13
JP2010526278A (ja) 2010-07-29
EP2104744A4 (en) 2011-05-04
WO2008089236A3 (en) 2010-01-07
HK1154052A1 (en) 2012-04-13
NZ596471A (en) 2013-11-29
NZ578164A (en) 2011-12-22
IL198677A (en) 2013-03-24
US20100029560A1 (en) 2010-02-04
JP5653042B2 (ja) 2015-01-14
US8445444B2 (en) 2013-05-21
KR101565080B1 (ko) 2015-11-03
AU2008206258A2 (en) 2009-10-29
EP2104744B1 (en) 2012-05-16
US20120058130A1 (en) 2012-03-08
US8088603B2 (en) 2012-01-03
ES2390083T3 (es) 2012-11-06
KR20090101442A (ko) 2009-09-28
IL198677A0 (en) 2010-02-17
CN101970685B (zh) 2013-08-07
US20110229492A1 (en) 2011-09-22
AU2008206258A1 (en) 2008-07-24
CN101970685A (zh) 2011-02-09
AP2009004851A0 (en) 2009-06-30
CA2667364A1 (en) 2008-07-24
AU2008206258B2 (en) 2013-06-13
EP2104744A2 (en) 2009-09-30

Similar Documents

Publication Publication Date Title
IL198677A0 (en) Compositions and methods for diagnosing, treating , and preventing prostate conditions
PL2173379T3 (pl) Kompozycje oraz sposoby leczenia i diagnozowania nowotworu
HRP20190214T1 (hr) Pripravci i metode za liječenje purpure
ZA200901615B (en) Compositions and methods for diagnosing and treating cancer
PL2032166T3 (pl) Kompozycje i sposoby diagnozowania i leczenia nowotworów
IL208366A0 (en) Compositions and methods for treating and diagnosing asthma
IL257681A (en) Methods and compositions for the treatment of cancer
SMT202300082T1 (it) Metodi e composizioni per il trattamento dei disturbi associati al complemento
EP2076116A4 (en) COMPOSITIONS, METHODS, AND DEVICES FOR TREATING HEPATIC DISEASES
EP2170309A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES
WO2009108860A3 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
GB2466912B (en) Compositions and methods for treating lysosomal disorders
SI2500360T1 (sl) Sestavki in postopki za diagnosticiranje in zdravljenje raka
IL210097A0 (en) Compositions and methods for treating unfluenza
SI2187967T1 (sl) Postopki in sestavki za zdravljenje raka
EP2137213A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER
PL2262828T3 (pl) Kompozycje, sposoby i zestawy
EP2424549A4 (en) COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING UROLITHIASIS AND ASSOCIATED SUFFERINGS
ZA201101520B (en) Phenanthrenone compounds,compositions and methods